Following Clearside Biomedical, Inc.?
Get the free weekly contract digest
The latest new contracts, like Clearside Biomedical, Inc.’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Clearside Biomedical's Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy
Nov 07, 2024•over 1 year ago
Contract Type
partnership
AlpharettaInformation TechnologyBiotechnologyHealthcarePharmaceuticalBiopharmaDescription
Clearside Biomedical, Inc. (Nasdaq: CLSD)'s Asia-Pacific partner, Arctic Vision, has signed a new commercial collaboration agreement with Santen Pharmaceutical Co., Ltd. for ARVN001, branded in the U.S. as XIPERE®, for the treatment of uveitic macular edema (UME) and certain other ophthalmic indications under development
Related People
Suggested for you
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months